Home Preparation and quality control of 166Ho-DTPA-antiCD20 for radioimmunotherapy
Article
Licensed
Unlicensed Requires Authentication

Preparation and quality control of 166Ho-DTPA-antiCD20 for radioimmunotherapy

  • Samaneh Zolghadri , A. R. Jalilian , Hassan Yousefnia , A. Bahrami-Samani , Simindokht Shirvani-Arani and M. Ghannadi-Maragheh
Published/Copyright: February 7, 2011

Abstract

In this work, anti-CD20 was successively labeled with beta-particle emitting radionuclide, Ho-166, for ultimate radioimmunotherapy applications. Ho-166 chloride was obtained by thermal neutron flux (1×1013 n cm−2 s−1) of natural Ho2(NO3)3 sample, dissolved in acidic media. 166Ho-holmium chloride (185 MBq) was added to the conjugated antibody after ccDTPA residulation at room temperature. Radiochemical purity of 95% (ITLC) and 98% (HPLC) were obtained for final radioimmunoconjugate (specific activity =3–3.5 GBq/mg). The final isotonic 166Ho-rituximab complex was checked by gel electrophoresis for protein integrity retention. Biodistribution studies of Ho-166 chloride and radioimmunoconjugate were performed in wild-type rats to determine the biodistribution. The accumulation of the radiolabeled antibody in lungs, liver and spleen demonstrates a similar pattern to the other radiolabeled anti-CD20 immunoconjugates.


* Correspondence address: Radiopharmaceutical Research and Development Laboratory (RRDL), Nuclear Science and Tecnology Research Institute, 14395-836 Tehran, Iran,

Published Online: 2011-02-07
Published in Print: 2011-04

© by Oldenbourg Wissenschaftsverlag, 14395-836 Tehran, Germany

Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1524/ract.2011.1826/html
Scroll to top button